XIAM007

Making Unique Observations in a Very Cluttered World

Tuesday 11 November 2014

Doctors testing Seniors for cocaine, heroin, and “angel dust” -- and Medicare pays the bill -

Doctors testing Seniors for cocaine, heroin, and “angel dust” -- and Medicare pays the bill - 

Dont do drugs.. Drugs are bad.... Mkay.<br /> Peace!. DONT DO DRUGS.. Drugs are bad mkay. downers, man

Doctors are testing seniors for drugs such as heroin, cocaine and “angel dust” at soaring rates, and Medicare is paying the bill.

It is a roundabout result of the war on pain-pill addiction.

Medical guidelines encourage doctors who treat pain to test their patients, to make sure they are neither abusing pills nor failing to take them, possibly to sell them.

Now, some pain doctors are making more from testing than from treating.

Spending on the tests took off after Medicare cracked down on what appeared to be abusive billing for simple urine tests. Some doctors moved on to high-tech testing methods, for which billing wasn’t limited.

They started testing for a host of different drugs—including illegal ones that few seniors ever use—and billing the federal health program for the elderly and disabled separately for each substance.

Medicare’s spending on 22 high-tech tests for drugs of abuse hit $445 million in 2012, up 1,423 percent in five years.

The program spent $14 million that year just on tests for angel dust, or PCP. Sue Brown, a laboratory director in Brunswick, Ga., said she has never seen someone over 65 test positive for angel dust, in 25 years in the business.

Read more - 
http://www.foxnews.com/politics/2014/11/11/doctors-testing-seniors-for-cocaine-other-drugs-and-medicare-pays-bill/

America's best-selling drug is ... Viagra? Prozac? Nah, it's actually an anti-psychotic called Abilify -

America's best-selling drug is ... Viagra? Prozac? Nah, it's actually an anti-psychotic called Abilify - 



America's best-selling drug is ... Viagra? Prozac? Nah, it's actually an anti-psychotic called Abilify that comes with two surprising factoids: It's designed to treat severe mental illnesses like schizophrenia and bipolar disorder but is now also widely prescribed for depression, and the U.S. Food and Drug Administration (FDA) can't explain how it works, the Daily Beast reports.

Americans, meanwhile, spent $6.9 billion on the drug between April 2013 and March 2014, topping sales of all other major anti-depressants combined. So what is Abilify? Ads by the drug's maker, Otsuka America, compare it to "a thermostat" that restores balance, PLOS Medicine reports, while a company rep says the drug's "mechanism of action" is described in a USPI insert that accompanies the medication.

Only problem: The USPI says that the "mechanism ... is unknown." "However, it has been proposed" that Abilify works "through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors," the USPI adds—yet that's only a proposal.

Testing has shown that Abilify successfully improves "quality of life" for schizophrenics, Reuters reports, but critics say that that makes Abilify "like a bazooka" compared to other anti-depressants.

Meanwhile, Abilify's ads promote the drug as a supplement to other anti-depressants. Abilify will surely add to the debate over whether anti-psychotics help people or simply zone them out, the Daily Beast notes, adding that Abilify "is extremely powerful medicine, being prescribed at an astonishingly high rate." (One study says that anti-depressants "change feelings of love.")

Read more - 
http://www.foxnews.com/health/2014/11/11/americas-best-selling-drug-isnt-one-youd-guess/?intcmp=latestnews

Scientists attempt a landing on a comet - like landing the head of a pin on the head of a pin, traveling at 84,000 mph -

Scientists attempt a landing on a comet - like landing the head of a pin on the head of a pin, traveling at 84,000 mph - 



Landing a probe on a comet whizzing through deep space isn't easy, but this week, the European Space Agency (ESA) will attempt to do just that. If successful, it will be the first time a probe has landed on the surface of a comet. 

Officials working with ESA's Rosetta mission are planning to land the robotic Philae probe on Comet 67P/Churyumov-Gerasimenko's surface Nov. 12. You can track Philae's historic progress in live webcasts from ESA and NASA starting Nov. 11 and throughout the day Wednesday. Officials on Earth should know if the landing went well by 11:02 a.m. EST on Nov. 12.

The landing is a risky operation.

Detailed mapping of Comet 67P/C-G only began in August, when Rosetta arrived carrying Philae. The comet's surface is strewn with boulders and cracks, and Philae's landing system has no way to maneuver at the last minute. [See amazing images from the Rosetta mission]

It will take about 7 hours for scientists on Earth to find out if Philae's trip to the surface was successful. A NASA video has even dubbed that block of time "7 hours of terror," an homage to the NASA Curiosity rover's "7 minutes of terror" video that described the Mars rover's landing sequence.

"This comet is very, very rough," Andreas Accomazzo, Rosetta operations manager at the European Space Agency, said in a Google+ Hangout Friday (Nov. 7). "But this is what we have, and this is what we are trying to do. We have to be a bit lucky as well."

First Comet Landing

If Philae's landing is successful, it will crown Rosetta's decade-long journey in space. The mission is doing the first orbit of a comet right now. Rosetta has already become the first spacecraft to orbit a comet, and if Philae safely touches down on Comet 67P/C-G, the lander will be the first to make a soft landing on a comet.

A comet is a tough environment. The gravity is so low that Philae will need to deploy a harpoon into the surface in order to stay put on Comet 67P/C-G. During landing, the spacecraft will face a dusty environment — not to mention, rocks on the surface. Success will also largely depend on how well the probe's hardware and software perform during those final few hours on the way down.

Rosetta planners will spend Nov. 10 and Tuesday looking at the landing orbit and preparing the parent spacecraft to release Philae. One of the busiest times will be late Tuesday night, when controllers have only 4 hours to send commands to Philae and make sure it's ready to go. [See more news about the Rosetta mission]

"We have 4 hours to put them together, check to verify they are consistent, uplink to the spacecraft ... and double-check they are OK to the spacecraft," Accomazzo said. "It's a pretty dense set of activities we have to do."

The plan then calls for Rosetta to release Philae Wednesday at 3:35 a.m. EST. (ESA officials on the ground will find out if the release was successful 28 minutes and 20 seconds later, once the signal reaches Earth.)

The spacecraft is too far away for controllers to do anything but hold their collective breath as the probe makes its descent. ESA mission controllers should acquire a signal from Philae during its descent at about 5:53 a.m. EST. Once that signal is established, Rosetta can start beaming back science information gathered by Philae on its way down to the comet's surface.

And by about 11 a.m. EST, scientists should know if Philae reached the surface.

Rosetta will also need to make several maneuvers to stay in touch with Philae during its descent, landing and post-landing activities. ESA added that both Rosetta and Philae appear to be in good shape to date, so they are planning for the best.

Not all science would die with Philae

Even if Philae doesn't successfully land, ESA anticipates that only 20 percent of the scientific findings expected to be gathered from the Rosetta mission would be lost. The remaining science would come from the orbital mission, which is projected to remain active until at least December 2015 — five months past Comet 67P/C-G's closest approach to the sun.

Philae's potential landing would make it the seventh location in which spacecraft have touched down outside Earth. The other bodies visited include Venus, the moon, Mars, Saturn's moon Titan, and asteroids 433 Eros and Itokawa.

"It's a very, very risky business, but it's a business in which we have invested a lot of know-how — a lot of technical know-how, a lot of scientific know-how and a lot of cooperation," Jocelyne Landeau-Constantin, head of European Space Operations Centre communications, said in the same webcast.

"Sometimes, we wake up and wonder if this dream is going to be true," she added. "Sometimes, we know it can go wrong. But we are ready for every option, and are still very confident we can make it."

Read more - 
http://www.foxnews.com/science/2014/11/11/risky-comet-landing-by-european-probe-will-be-7-hours-terror/